Aseptic preparation of parenteral medicinal products in healthcare establishments in Europe

HPA Scheepers; AM Beaney; PPH Le Brun; V Neerup Handlos; MDB Schutjens; S Walser; C Neef

doi:10.14748/.v2i1.1889

Aseptic preparation of parenteral medicinal products in healthcare establishments in Europe

HPA Scheepers, AM Beaney, PPH Le Brun, V Neerup Handlos, MDB Schutjens, S Walser, C Neef

Abstract

In many cases, parenteral medicines with a marketing authorisation cannot be administered directly to patients, that is, they are not presented in ready-to-administer form. Before administration to patients, these medicines have to be reconstituted. Reconstitution has a special position; it can neither be seen as industrial manufacture nor as ‘regular` pharmacy preparation. There are other processes in healthcare establishments (eg, parenteral nutrition), related to the reconstitution process, where the requirements of national quality assurance standards for the safe preparation of sterile products are equally important and have to be fulfilled. In European healthcare establishments, aseptic preparation of parenteral medicinal products is considered to be a process of crucial importance for patient safety because errors in the preparation of these medicines may lead to a product that can cause immediate damage to patients. Aseptic preparation of medicinal products is carried out in hospital pharmacies as well as in clinical areas in healthcare establishments. The Committee of Experts on Quality and Safety Standards for Pharmaceutical Practices and Pharmaceutical Care (Council of Europe; hereafter: Committee of Experts), supported by the European Directorate for the Quality of Medicines & Healthcare, is undertaking work on the topic of aseptic preparation of medicines. The work is carried out in cooperation with the European Association of Hospital Pharmacists on the basis of a Resolution CM/Res AP(2011)1 on Quality and Safety Assurance requirements for Medicinal Products prepared in Pharmacies for the Special Needs of Patients, which was adopted by the Committee of Ministers on 19 January 2011. The Resolution includes some recommendations and an outlook to further work on reconstitution of parenteral medicines. A survey that was sent to the different European countries demonstrated that there is no or just limited regulation concerning reconstitution in Europe. This article describes the risks associated with poor reconstitution practices and the previous work as well as the ongoing activities concerning reconstitution at the European level. The article emphasises the need for regulation in this area, which is missing at present. It is expected that consensus can be reached on a guidance document for reconstitution at the European level.

Full Text

References

Resolution CM/Res AP(2011)1 on quality and safety assurance requirements for medicinal products prepared in pharmacies for the special needs of patients. Council of Europe.

EU GMP. Eudralex Volume 4 Good Manufacturing Practice. http://ec.europa.eu/ health/documents/eudralex/vol-4/index_en.htm (accessed 2 Apr 2015).

Ter Huurne K, Hendrix MGR, Colen HBB, et al. Again question marks with complex preparation activities. Nurses and preparation protocol of syringes. (Opnieuw vraagtekens bij complexe bereidingshandelingen. Verpleegkundigen en spuitbereidingsprotocollen.) Pharm Weekbl 2002;137:1383-7.

McDowell SE, Mt-lsa S, Ashby D, et al. Where errors occur in the preparation and administration of intravenous medicines: a systematic review and Bayesian analysis. Qual Saf Health Care 2010;19:341-5.

Han PY, Coombes ID, Green B. Factors predictive of intravenous fluid administration errors in Australian surgical care wards. Qual Saf Health Care 2005;14:179-84.

Hertzel C, Sousa VD. The use of smart pumps for preventing medication errors. J Infus Nurs 2009;32:257-67.

Malashock CM, Shull SS, Gould DA. Effect of smart infusion pumps on medication errors related to infusion device programming. Hosp Pharm 2004;39:460-9.

Garrouste-Orgeas M, Timsit JF, Vesin A, et al. Selected medical errors in the intensive care unit: results of the IATROREF study: parts I and II. Am J Respir Crit Care Med 2010;181:134-42.

Calabrese AD, Erstad BL, Brandl K, et al. Medication administration errors in adult patients in the ICU. Intensive Care Med 2001;27:1592-8.

Rothschild JM, Keohane CA, Cook EF, et al. A controlled trial of smart infusion pumps to improve medication safety in critically ill patients.* Crit Care Med 2005;33:533-40. (*See also pg 679.)

Valentin A, Capuzzo M, Guidet B, et al. Errors in administration of parenteral drugs in intensive care units: multinational prospective study. BMJ 2009;338:b814.

Kohn LT, Corrigan JM, Donaldson MS, Committee on quality of health care in America, Institute of Medicine. To Err is Human: Building a Safer Health System. Washington: National Academy Press, 2000.

Cousins DH, Sabatier B, Begue D, et al. Medication errors in intravenous drug preparation and administration: a multicentre audit in the UK, Germany and France. Qual Saf Health Care 2005;14:190-5.

Wirtz V, Taxis K, Barber ND. An observational study of intravenous medication errors in the United Kingdom and in Germany. Pharm World Sci 2003;25:104-11.

Taxis K, Barber N. Incidence and severity of intravenous drug errors in a German hospital. Eur J Clin Pharmacol 2004;59:815-17.

Rothschild JM, Landrigan CP, Cronin JW, et al. The Critical Care Safety Study: the incidence and nature of adverse events and serious medical errors in intensive care. Crit Care Med 2005;33:1694-700.

Phillips J, Beam S, Brinker A. Retrospective analysis of mortalities associated with medication errors. Am J Health Syst Pharm 2001;58:1835-41.

Van den Bemt PMLA, Egberts TCG, De Jong-van den Berg LTW, et al. Drug related problems in hospitalised patients [thesis], adverse events and medication errors systematically classified. Drug related problems defined and classified. Groningen: Rijksuniversiteit Groningen; Pharmaceutisch Weekblad 2002;137:1540-3.

Roelofsen EE, et al. Safety on prescription: a protocol for improving parenteral medication preparation and administration by nurses on the ward. (Veiligheid op recept: een protocol voor veilig voor toediening gereed maken en toedienen van parenteralia door verpleegkundigen.) Pharm Weekbl., wetenschappelijk platform 2007:78-83.

Van Grafhorst JP, Foudraine NA, Nooteboom F, et al. Clean appearances are deceptive. Preparing of syringes for continuous intravenous drug administration in the intensive care unit. (Schone schijn bedriegt. Bereiding van perfusorspuiten op de intensive care.) Pharm Weekbl 2001;136:732-7.

Bennett SN, McNeil MM, Bland LA, et al. Postoperative infections traced to contamination of an intravenous anaesthetic, propofol. N Engl J Med 1995;333:147-54.

Tallis GF, Ryan GM, Lambert SB, et al. Evidence of patient-to-patient transmission of hepatitis C virus through contaminated intravenous anaesthetic ampoules. J Viral Hepat 2003;10:234-9.

Seres D, Sacks GS, Pederssen CA, et al. Parenteral nutrition safe practices: results of the 2003 American Society for Parenteral and Enteral Nutrition survey. J Parenter Enteral Nutr 2006;30:259-65.

Report from GERPAC conference, 2013. http://www.gerpac. eu/spip.php?article957 (accessed 17 Oct 2014).

Deutsche Welle article 20.08.10. http://www.dw.de/ two-babies-dead-five-critical- from-bacteria-at-germanhospital/ a-5933837 (accessed 17 Oct 2014).

Scheepers HPA, Busch G, Hofbauer E, et al. Abridged survey report on quality and safety assurance standards for the preparation of medicinal products in pharmacies.

Pharmeuropa 2010;22. 27. `Promoting Standards for the Quality and Safety Assurance of Pharmacy-Prepared Medicinal Products for the Needs of Patients`, (24 September 2009 at the European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, in Strasbourg). http://www.edqm.eu/en/qualityand- safety-standards-1244. html (accessed 17 Oct 2014).

CDC, Centers for Disease Control and Prevention, Multistate Outbreak. Multistate Outbreak of Fungal Infection Associated with Injection of Methylprednisolone Acetate Solution from a Single Compounding Pharmacy - United States, 2012.

US Food and Drug Administration (FDA). CDC and ADPH investigate outbreak at Alabama hospitals; products recalled. (29 March, 2011). http://www.fda.gov/Safety/ Recalls/ ucm249068.htm (accessed 17 Oct 2014).

Wolfson H. Investigators piecing together tainted IV puzzle after deaths in Alabama hospitals. The Birmingham News 2011. http://blog.al.com/spotnews/2011/04/ investigators_ piecing_together.html (accessed 17 Oct 2014).

National Patient Safety Agency. Patient Safety Alert: promoting safer use of injectable medicines 20. http:// www.nrls.npsa.nhs.uk/resources? entryid45=59812&p=3 (accessed 17 Oct 2014).

Bates DW, Vanderveen T, Seger DL, et al. Variability in intravenous medication practices: implications for medication safety. Jt Comm J Qual Patient Saf 2005;26:203-10.

Eskew JA, Jacobi J, Buss W, et al. Using innovative technologies to set new safety standards for the infusion of intravenous medications. Hosp Pharm 2002;37:1179-89.

DOI: http://dx.doi.org/10.14748/.v2i1.1889